Current Radiopharmaceuticals

Aims & Scope

Current Radiopharmaceuticals publishes original research articles, letters, full-length/mini-reviews, drug clinical trial studies, and guest-edited issues on all aspects of research and development of radiolabelled compound preparations, covering studies related to nuclear medicine, molecular imaging, radiotherapy, neuroradiology, interventional radiology, investigative radiology, oncology, and basic research.

The scope of the journal also covers the following areas, namely radio imaging techniques, computerized medical images and graphics, preparation and application of radionuclide compounds, and their diagnostic, investigative, and therapeutic use, including the incorporation of tracer methods used in scientific research and applications.

Articles related to the resources on radiation research in the field of biology and biophysics are also included.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	1.2
2024	1.50

Journal Rank

Year	Value
2024	16742

Journal Citation Indicator

Year	Value
2024	143

SJR (SCImago Journal Rank)

Year	Value
2024	0.297

Quartile

Year	Value
2024	Q3

h-index

Year	Value
2024	35

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• An Overview of Targeted Alpha Therapy with ²²⁵Actinium and ²¹³Bismuth

  Citation: 297

  Authors: Alfred, Christos, Clemens, Mike, Leszek, Frank

• Development of ²²⁵Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

  Citation: 162

  Authors: Andrew Kyle Henderson, Caterina Fortunata, Paul, Valery

• Astatine-211: Production and Availability

  Citation: 157

  Authors: Michael, Marek

• PET Tracers Based on Zirconium-89

  Citation: 138

  Authors: Yin, Hao, Weibo

• Actinium-225 in Targeted Alpha-Particle Therapeutic Applications

  Citation: 136

  Authors: David, Michael

• Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes

  Citation: 111

  Authors: Alfred, Frank, Christos

• Scandium-44: Benefits of a Long-Lived PET Radionuclide Available from the 44Ti/44Sc Generator System

  Citation: 101

  Authors: F.

• Targeted Radionuclide Therapy - An Overview

  Citation: 84

  Authors: Ashutosh, F. F., M.

• Mechanisms of Radiation Bystander and Non-Targeted Effects: Implications to Radiation Carcinogenesis and Radiotherapy

  Citation: 76

  Authors: Rasoul, Elahe, Abolhasan, Hamid, Bagher, Mohsen, Masoud, Vilmar

• Synthesis of [18F]Fallypride in a Micro-Reactor: Rapid Optimization and Multiple-Production in Small Doses for Micro-PET Studies

  Citation: 72

  Authors: Shuiyu, Anthony, Victor

---